Neurological Surgery No Shinkei Geka Volume 27, Issue 11 (November 1999)

Combined Modality Therapy for Malignant Lymphoma of the Primary Central Nervous System : a preliminary report of a new chemotherapeutic regimen with “PEACE” Atsushi KEYAKI 1,2 , Sachio NABESHIMA 2 , Shiro WAGA 1 1Department of Neurosurgery, Osaka Saiseikai Izuo Hospital 2Department of Neurosurgery, Tenri Hospital Keyword: central nervous system , malignant lymphoma , chemotherapy , radiotherapy , non-Hodgkin's lymphoma pp.999-1005
Published Date 1999/11/10
  • Abstract
  • Look Inside

Between 1994 and 1998, a total of 5 patients with primary central nervous system malignant lymphoma(PCNSML) were enrolled in this study. There were one man and four women, with a median age of 53years. These patients were treated with a new systemic chemotherapeutic regimen “PEACE” therapy. Af-ter undergoing surgery (biopsy or resection), the patients received radiotherapy followed by adjuvant che-motherapy with combination of procarbazine (P) (100mg/clay, p.o., dayl to day5), cyclophosphamide (E) (200mg/sqm/day, day4), doxorubicin hydrochloride (A) (20mg/sqm/day, day4 and day5), carboplatin (C)(300mg/sqm/day, day1), and etoposide (E) (30mg/scim/clay, dayl to day3). This regimen was repeatedfor at least three cycles every 4 to 6 weeks. Intrathecal injection of methotrexate was also administrated inconjunction with systemic chemotherapy except in one case. Complete response was seen in one, and par-tial response in four patients. Toxicity was tolerable. Median survival time was 31.5 months. The resultssuggest the efficacy of this chemotherapeutic regimen and further emphasize a role for adjuvant chemothe-rapy in the initial treatment of PCNSML.

Copyright © 1999, Igaku-Shoin Ltd. All rights reserved.


Neurological Surgery 脳神経外科
27巻11号 (1999年11月)
電子版ISSN 1882-1251 印刷版ISSN 0301-2603 医学書院